The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.
Spironolactone (S) has been used successfully for the treatment of hirsutism. We evaluated whether the effects of S on serum androgens and hair growth are dose-related and whether S affects secreted androgens to the same degree as peripherally derived androgens. Two groups of 15 hirsute patients, similarly matched, received either 100 or 200 mg S daily for 3 months. Serum total testosterone (T) decreased significantly (P less than 0.05) and to a similar degree with both dosages, whereas unbound T was unaltered. Dehydroepiandrosterone sulfate was unaltered, whereas androstenedione decreased with 200 mg S (P less than 0.05). Peripherally derived serum dihydrotestosterone decreased to a similar degree with 100 and 200 mg S (P less than 0.05), whereas 5 alpha-androstane-3 alpha-17 beta-diol (3 alpha-diol) increased (P less than 0.05) similarly with both dosages. Serum 3 alpha-diol glucuronide (3 alpha-diol-G) increased with both dosages, but not significantly. Anagen hair shaft diameters decreased significantly in both groups by 19% +/- 8% and 30% +/- 4% (P less than 0.05). No correlation was found between hair growth and serum androgens. Because serum unbound T was largely unaltered by S, it is suggested that the antiandrogenic effects of S are primarily related to its peripheral effect. However, there is no good clinical marker for this effect as levels of 3 alpha-diol and 3 alpha-diol-G increase.
D000328:Adult; D000726:Androgen Antagonists; D000728:Androgens / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006197:Hair / Q000187:drug effects* / Q000254:growth & development; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use*
D000726:Androgen Antagonists; D000728:Androgens; D013148:Spironolactone